Combining PD-L1 and VEGF Blockade for Brain Metastasis Treatment
Author Information
Author(s): Masuda Chinami, Onishi Shinichi, Yorozu Keigo, Kurasawa Mitsue, Morinaga Mamiko, Wakita Daiko, Sugimoto Masamichi
Primary Institution: Chugai Pharmaceutical Co., Ltd.
Hypothesis
Does the dual blockade of PD-L1 and VEGF enhance anti-tumor effects on brain metastases?
Conclusion
The combination of anti-PD-L1 and anti-VEGF antibodies shows a stronger anti-tumor effect on brain metastases compared to each treatment alone.
Supporting Evidence
- The combination treatment increased intratumoral CD8+ cell density in the brain parenchyma and ventricular metastases.
- Anti-PD-L1 antibody alone enhanced CD8+ T cell priming in regional lymph nodes.
- Anti-VEGF antibody decreased microvessel density in ventricular metastases.
Takeaway
This study found that using two different treatments together can help fight cancer that has spread to the brain better than using just one treatment.
Methodology
Mice with brain metastases were treated with anti-PD-L1 and anti-VEGF antibodies, and tumor burden was assessed using luciferase activity.
Potential Biases
Potential bias due to the use of a single tumor model and the specific immune environment of the model.
Limitations
The study is based on a single cell line model, which may limit the generalizability of the findings.
Participant Demographics
Female C3H/HeNCrl mice, 7-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website